Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and | Xetra | Healthcare | Pharmaceuticals | €698.98B | 71.6x | 0.72 | €778.80 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eli Lilly | Vienna | Healthcare | Pharmaceuticals | €697.59B | 71.6x | 0.72 | €773 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eli Lilly and | Frankfurt | Healthcare | Pharmaceuticals | €691.07B | 70.8x | 0.72 | €774.60 | -3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
UnitedHealth | Vienna | Healthcare | Healthcare Providers & Services | €412.62B | 31.3x | -0.89 | €456.60 | 3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
UnitedHealth Group | Frankfurt | Healthcare | Healthcare Providers & Services | €407.43B | 30.7x | -0.9 | €448.35 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson & Johnson | Vienna | Healthcare | Pharmaceuticals | €376.11B | 28.9x | -0.49 | €156.04 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson&Johnson | Xetra | Healthcare | Pharmaceuticals | €376.03B | 28.9x | -0.49 | €155.88 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson | Frankfurt | Healthcare | Pharmaceuticals | €372.54B | 28.7x | -0.49 | €155.76 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbvie | Vienna | Healthcare | Pharmaceuticals | €355.13B | 90.7x | -7.36 | €196.32 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie | Frankfurt | Healthcare | Pharmaceuticals | €354.65B | 90.2x | -7.36 | €201.25 | 4.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk A S | Xetra | Healthcare | Pharmaceuticals | €327.34B | 24.1x | 1.22 | €73.80 | -8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk A S | Frankfurt | Healthcare | Pharmaceuticals | €327.34B | 24.1x | 1.22 | €73.59 | -8.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk AS | Vienna | Healthcare | Pharmaceuticals | €327.34B | 24.1x | 1.22 | €73.70 | -8.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk B | BATS Europe | Healthcare | Pharmaceuticals | €326.97B | 24.1x | 1.13 | €73.47 | -8.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche | BATS Europe | Healthcare | Pharmaceuticals | €270.58B | 31.1x | -1.06 | €339.98 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche | BATS Europe | Healthcare | Pharmaceuticals | €270.58B | 31.1x | -1.06 | €322.03 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding DRC | Frankfurt | Healthcare | Pharmaceuticals | €269.58B | 31.1x | -1.06 | €40.11 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Xetra | Healthcare | Pharmaceuticals | €224.74B | 14.2x | 0 | €88.60 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Milan | Healthcare | Pharmaceuticals | €224.57B | 14.2x | -8.78 | €88.20 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck & Co | Vienna | Healthcare | Pharmaceuticals | €224.57B | 14.2x | 0 | €89.10 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Frankfurt | Healthcare | Pharmaceuticals | €222.16B | 14.1x | 0 | €88.10 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbott Laboratories | Vienna | Healthcare | Healthcare Equipment & Supplies | €221.93B | 18x | 0.13 | €125.56 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbott Laboratories | Xetra | Healthcare | Healthcare Equipment & Supplies | €221.87B | 18x | 0.13 | €127.96 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbott Laboratories | Frankfurt | Healthcare | Healthcare Equipment & Supplies | €219.93B | 17.9x | 0.13 | €127.38 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astrazeneca | BATS Europe | Healthcare | Pharmaceuticals | €218.97B | 33.7x | 1.9 | €141.08 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca DRC | Frankfurt | Healthcare | Pharmaceuticals | €218.94B | 33.7x | 1.9 | €72 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astrazeneca PLC | Xetra | Healthcare | Pharmaceuticals | €218.94B | 33.7x | 1.9 | €141.55 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | Frankfurt | Healthcare | Pharmaceuticals | €218.94B | 33.7x | 1.9 | €142.05 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca DRC | Vienna | Healthcare | Pharmaceuticals | €218.94B | 33.7x | 1.9 | €71.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca PLC | BATS Europe | Healthcare | Pharmaceuticals | €218.72B | 33.7x | 1.87 | €141.55 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | BATS Europe | Healthcare | Pharmaceuticals | €210.78B | 19.5x | -1.09 | €106.51 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Thermo Fisher Scientific | Vienna | Healthcare | Healthcare Equipment & Supplies | €185.40B | 32.1x | 4.53 | €484.40 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Xetra | Healthcare | Pharmaceuticals | €165B | 43.5x | -1.08 | €306.05 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Vienna | Healthcare | Pharmaceuticals | €164.83B | 43.5x | -1.08 | €300.05 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Frankfurt | Healthcare | Pharmaceuticals | €162.52B | 43x | -1.08 | €296.65 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Intuitive Surgical | Vienna | Healthcare | Healthcare Equipment & Supplies | €160.14B | 74.8x | 2.88 | €468.10 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Intuitive Surgical | Frankfurt | Healthcare | Healthcare Equipment & Supplies | €159.70B | 73.3x | 2.88 | €444.90 | -6.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Xetra | Healthcare | Pharmaceuticals | €141.29B | 18.9x | 0.07 | €24.88 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Vienna | Healthcare | Pharmaceuticals | €141.29B | 18.9x | 0.07 | €24.89 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Frankfurt | Healthcare | Pharmaceuticals | €139.14B | 18.8x | 0.07 | €24.74 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | Frankfurt | Healthcare | Pharmaceuticals | €137.32B | 24.7x | 8.51 | €110 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi SA | Xetra | Healthcare | Pharmaceuticals | €137.32B | 24.7x | 8.51 | €109.74 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | Milan | Healthcare | Pharmaceuticals | €137.32B | 24.7x | 8.51 | €109.74 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | Paris | Healthcare | Pharmaceuticals | €137.32B | 24.7x | 8.51 | €109.48 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.5% Upside | Upgrade to Pro+ | |
Sanofi | BATS Europe | Healthcare | Pharmaceuticals | €137.32B | 24.7x | 8.55 | €109.65 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | Vienna | Healthcare | Pharmaceuticals | €137.32B | 24.7x | 8.51 | €109.24 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Xetra | Healthcare | Pharmaceuticals | €136.84B | 308.3x | -3.33 | €109.72 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Milan | Healthcare | Pharmaceuticals | €136.83B | 308.3x | -3.33 | €110.40 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Vienna | Healthcare | Pharmaceuticals | €136.83B | 308.3x | -3.33 | €107.86 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Danaher | Vienna | Healthcare | Healthcare Equipment & Supplies | €136.58B | 39x | -2.27 | €195.38 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |